CIPLA
Back to Cashflow Statement
|
CIPLA Last 5 Year Cash Flow from Financing Activities History
[Consolidated]
Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
---|---|---|---|---|---|
Cash Flow from Financing Activities | ₹-1,293 Cr | ₹-1,200 Cr | ₹-958 Cr | ₹-1,600 Cr | ₹-1,240 Cr |
What is the latest Cash Flow from Financing Activities ratio of CIPLA ?
Year | Cash Flow from Financing Activities |
---|---|
Mar2025 | ₹-1,293 Cr |
Mar2024 | ₹-1,200 Cr |
Mar2023 | ₹-958 Cr |
Mar2022 | ₹-1,600 Cr |
Mar2021 | ₹-1,240 Cr |
How is Cash Flow from Financing Activities of CIPLA Trending?
Years | Cash Flow from Financing Activities | % Change | |
---|---|---|---|
Mar2025 | ₹-1,293 Cr | Negative | |
Mar2024 | ₹-1,200 Cr | Negative | |
Mar2023 | ₹-958 Cr | Negative | |
Mar2022 | ₹-1,600 Cr | Negative | |
Mar2021 | ₹-1,240 Cr | - |
Compare Cash Flow from Financing Activities of peers of CIPLA
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
CIPLA | ₹127,499.1 Cr | 0.3% | 1.9% | -6.1% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹395,626.0 Cr | 2% | 1.4% | -13% | Stock Analytics | |
DIVIS LABORATORIES | ₹161,996.0 Cr | 1.3% | 0.3% | 10.4% | Stock Analytics | |
TORRENT PHARMACEUTICALS | ₹120,718.0 Cr | 0% | -2.3% | 2.6% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹110,374.0 Cr | 0.5% | 6.2% | -1.4% | Stock Analytics | |
MANKIND PHARMA | ₹108,892.0 Cr | 2.3% | 5.9% | 4.6% | Stock Analytics |
CIPLA Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
CIPLA | 0.3% |
1.9% |
-6.1% |
SENSEX | 1.8% |
2.1% |
0.2% |
You may also like the below Video Courses